Pavmed
Pavmed Inc., a pioneering medical technology company headquartered in the United States, was founded in 2014. The company focuses on developing innovative solutions across various medical fields, including gastroenterology, urology, and general surgery. With a commitment to enhancing patient care, Pavmed has introduced unique products such as the EsoGuard® and the CarpX® device, which stand out for their advanced design and efficacy. Operating primarily in the US, Pavmed has achieved significant milestones, including successful clinical trials and regulatory approvals that underscore its market position. The company is dedicated to addressing unmet medical needs, making it a notable player in the medical device industry. With a strong emphasis on innovation and patient outcomes, Pavmed continues to shape the future of healthcare technology.
DitchCarbon Score
How does Pavmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pavmed's score of 25 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pavmed's reported carbon emissions
In 2023, Pavmed Inc., headquartered in the US, reported total carbon emissions of approximately 115,790 kg CO2e, comprising 65,440 kg CO2e from Scope 1 and 50,350 kg CO2e from Scope 2 emissions. This data reflects a commitment to transparency in their environmental impact, although no Scope 3 emissions data has been disclosed. Comparatively, in 2022, Pavmed's emissions in the US were about 97,620 kg CO2e, with 61,200 kg CO2e from Scope 1 and 36,420 kg CO2e from Scope 2. This indicates a slight increase in total emissions from 2022 to 2023. Pavmed has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests a need for further development in their climate strategy. Overall, while Pavmed has made strides in reporting their emissions, the lack of reduction commitments highlights an area for potential growth in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 611,839,000 |
| Scope 2 | 241,103,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pavmed is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
